The journal European Child & Adolescent Psychiatry recently published the results of a systematic review and dose-response meta-analysis evaluating the relationship between maternal 25-hydroxyvitamin D (25(OH)D) levels during pregnancy and the risk of diagnosis and symptoms of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children. This analysis included a total of 15 studies with a mix of case-control and cohort studies investigating either a diagnosis or symptoms of ADHD or ASD. Analysis of the 8 studies investigating ASD found a “consistent evidence of a protective association of vitamin D,” with an overall 9% significant reduction in ASD diagnosis. This appeared to be a dose-dependent linear relationship; for every 10 nmol/L increase in maternal 25(OH)D there was a 9% lower risk. For example, for mothers with the highest 25(OH)D of 90 nmol/L, there was approximately a 50% lower incidence of ASD diagnosis. There was also a small but significant reduction in ASD symptoms with higher 25(OH)D levels. Similar results were found for ADHD, with an approximately a 10% overall significant reduction in risk for a diagnosis, and a small but non-significant reduction in symptoms.
A number of plausible mechanisms of action are suggested by the authors, primarily related to a beneficial role of vitamin D in fetal brain development, including modulation of neurotransmitter synthesis and regulation of immune/inflammatory pathways, as well as neuron growth and development. For example, a number of preclinical studies suggest that maternal immune activation, marked by oxidative stress, mitochondrial dysfunction, neuroinflammation (with an upregulation of inflammatory cytokines), etc., may be contributing factors. In one experimental mouse study, vitamin D supplementation during pregnancy helped to alleviate this immune activation, inhibiting inflammatory cytokine production and improving ASD-like behavior in offspring.
There is some evidence in humans that 25(OH)D during pregnancy may be more important than during early childhood, at least in terms of ASD risk. For example, in one double-blind, randomized controlled trial known as the vitamin D intervention in infants (VIDI), nearly 400 Finnish children aged 6 to 8 were given either 400 IU or 1200 IU vitamin D3 when they were between 2 weeks and 2 years old. There was no significant benefit of the higher dose (and no placebo to compare with), though 25(OH)D levels among boys (not girls) were inversely associated with scores on the Autism Spectrum Screening Questionnaire (ASSQ). Thus, it’s not clear that supplementation during early childhood lowers risk, though risk was still linked to 25(OH)D during infancy, at least in boys.
In one older study with no placebo and an open-label design (thus inherently limited in its conclusions), women who had previously had a child with ASD were supplemented with vitamin D during pregnancy (5,000 IU per day), with their children supplemented at 1,000 IU per day until reaching age 3 (nursing mothers were also supplemented at 7,000 IU per day). Although a small study, they report only 1 child developing ASD (5%) compared to a literature prevalence of 20%. More studies evaluating multiple doses, potentially influenced by BMI and other factors, given at various time points (before conception, during pregnancy, etc.) may help to establish potential benefit, and if there is an optimal window for supplementation.